PARKINSON’S DISEASE — LONG-TERM THERAPY WITH LEVODOPA

InPharma ◽  
1975 ◽  
Vol 10 (1) ◽  
pp. 8-8
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Term Therapy ◽  
Long Term Therapy

scholarly journals Manganese increases L-DOPA auto-oxidation in the striatum of the freely moving rat: potential implications to L-DOPA long-term therapy of Parkinson's disease

2000 ◽  
Vol 130 (4) ◽  
pp. 937-945 ◽  
Author(s):  
Pier Andrea Serra ◽  
Giovanni Esposito ◽  
Paolo Enrico ◽  
Maria A Mura ◽  
Rossana Migheli ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Term Therapy ◽  
Freely Moving ◽  
Long Term Therapy

Alpha-dihydroergocryptine in the Long term Therapy of Parkinson’s Disease

2011 ◽  
Vol 54 (10) ◽  
pp. 647-654
Author(s):  
Enrico Mailland ◽  
Paola Magnani ◽  
Bertram Ottillinger
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Term Therapy ◽  
Long Term Therapy

Balancing Short-Term Symptom Control and Long-Term Functional Outcomes in Patients with Parkinson's Disease

CNS Spectrums ◽  
2007 ◽  
Vol 12 (4) ◽  
pp. 275-286 ◽  
Author(s):  
James W. Tetrud
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Functional Outcomes ◽  
Symptom Control ◽  
Symptomatic Treatment ◽  
Term Therapy ◽  
Motor Complications ◽  
Short Term ◽  
Long Term Therapy

ABSTRACTLevodopa has played a central role in the treatment of Parkinson's disease for nearly 40 years and remains the single most effective symptomatic treatment for the disease. However, the response to levodopa therapy changes over time, and its long-term use is commonly associated with disabling motor complications. For this reason, the appropriate role of levodopa in the treatment of Parkinson's disease—in particular, the question of when to initiate therapy with the drug—has been a matter of controversy. Because levodopa is the most effective treatment for Parkinson's disease, the management of this disease becomes a matter of balancing short-term symptom control with long-term functional outcomes. This article provides an overview of the basis for levodopa-associated motor complications and their impact on patients' clinical function and quality of life, followed by a discussion of strategies for managing these complications to achieve optimum symptom control while minimizing the adverse effects of long-term therapy.

scholarly journals Dopamine Therapy and the Regulation of Oxidative Stress and Mitochondrial DNA Copy Number in Patients with Parkinson’s Disease

Antioxidants ◽  
2020 ◽  
Vol 9 (11) ◽  
pp. 1159
Author(s):  
Shih-Hsuan Chen ◽  
Chung-Wen Kuo ◽  
Tsu-Kung Lin ◽  
Meng-Han Tsai ◽  
Chia-Wei Liou
Keyword(s):  
Oxidative Stress ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Mitochondrial Dna ◽  
Copy Number ◽  
Term Therapy ◽  
Tbars Level ◽  
Copy Numbers ◽  
Mitochondrial Copy Number

Few studies have reported on changes to oxidative stress and mitochondrial DNA copy numbers in patients with Parkinson’s disease (PD), particularly those undergoing long-term dopamine therapy. This study measured mitochondrial copy numbers, thiobarbituric acid reactive substances (TBARS), and thiols in 725 PD patients and 744 controls. The total prescribed dopamine dose was calculated for each PD patient. A decreased mitochondrial copy number and antioxidant thiols level, but an elevated oxidative TBARS level presented in PD patients. Stratification into age subgroups revealed a consistently lower mitochondrial copy number and thiols in all PD subgroups, but increased TBARS levels compared with those of the controls. Further study found an association between lower serum TBARS and dopamine administration. There appears to be an indirect relationship with the mitochondrial copy number, where a decrease in TBARS was found to diminish the effect of pathogenetic and age-related decrease in mitochondrial copy number in PD patients. Follow-up evaluations noted more significant decreases of mitochondrial copy numbers in PD patients over time; meanwhile, dopamine administration was associated with an initial decrease of the TBARS level which attenuated with high-dose and long-term therapy. Our study provides evidence that moderate dopamine dose therapy benefits PD patients through attenuation of oxidative stress and manipulation of the mitochondrial copy number.

Antithrombotic Therapy for DVT/PE

1997 ◽  
Vol 17 (03) ◽  
pp. 161-162
Author(s):  
Thomas Hyers
Keyword(s):  
Molecular Weight ◽  
Low Molecular Weight Heparin ◽  
Oral Anticoagulants ◽  
Cost Effective ◽  
Therapeutic Agents ◽  
Great Promise ◽  
Term Therapy ◽  
Low Molecular Weight ◽  
Long Term Therapy

SummaryProblems with unfractionated heparin as an antithrombotic have led to the development of new therapeutic agents. Of these, low molecular weight heparin shows great promise and has led to out-patient therapy of DVT/PE in selected patients. Oral anticoagulants remain the choice for long-term therapy. More cost-effective ways to give oral anticoagulants are needed.

Sign in / Sign up

Export Citation Format

Share Document